The diabetes market will reach $75.02bn in 2020, a new study predicts

05 September 2018
Pharma

A new report by visiongain forecasts the world diabetes market will reach $75.02bn in 2020.That revenue prediction and others appear in Diabetes World Drug Market Report 2016-2026: Insulin and Insulin Analogues, DPP-4 Inhibitors, Biguanides, GLP-1 Agonists, Alpha-glucosidases, SGLT-2 Inhibitors, Sulfonylureas and Others, published in July 2016. Visiongain is a business information publisher and consultancy in London, UK.

The analysis predicts the diabetes market will continue to grow at a CAGR of 8.97% from 2015-2020, driven by the injectable drugs segment. In 2015, Lantus was the leading diabetes drugs with revenues of $7.13bn. Insulins and insulin analogues will remain as the leading drug sub market throughout the coming decade.
The market for diabetes drugs will expand much more rapidly due to the aging of the general population, poor dietary habits and sedentary lifestyles, the latter two of which can be attributed to a growing urbanised and westernised population. These are all key risk factors for the development of type 2 diabetes. Type 1 diabetes is expected grow more in line with the growth of the population.
Robert King, a pharmaceutical and healthcare industry analyst in visiongain, said:
“The diabetes drug market has consistently outperformed the global pharmaceutical market. Visiongain predicts this trend to continue as the increase in diabetes prevalence will drive this therapeutic area up to and beyond the forecast period of this report. The incidence of diabetes among younger people especially is expected to grow significantly, due to poor diets and enhanced diagnosis rates as a result of more effective screening methods. Patients in this particular population group are more likely to be well insured and also represent a longer per-patient market opportunity for diabetes drug manufacturers in chronic monitoring and therapeutic regimens.
Patient demographics mask the true scale of the growing diabetes epidemic worldwide, as it does not take into account the undiagnosed population. This is especially true for type 2 diabetes and also for people in developing countries. Although the current public health spotlight on diabetes has increased and newer screening methods and criteria have emerged, leading to an increase in the diagnosed population, the undiagnosed population remains hidden and can represent up to 50% of the total. It is important that improvements are made in diabetes awareness, by both industry participants and public health communities, so that the undiagnosed population have access to treatments in the near future”
This report investigates commercial trends and revenues of the diabetes market from 2016 to 2026, as well as including data from 2015. This report discusses sales potentials of:

• The drugs market divided into two key segments:
o Injectables
o Non-injectables
• The drugs market further divided across 9 submarkets
o Insulins/insulin analogues
o DPP-4 Inhibitors
o Biguanides
o Sulfonylureas
o GLP-1 agonists
o Meglitinides
o SGLT-2 Inhibitors
o Alpha-glucosidases
o Thiazolidinediones

• 11 leading individual national markets including:
o US
o Japan
o EU5 (Germany, France, UK, Italy and Spain)
o BRIC (Brazil, Russia, India and China)

This report qualitatively discusses:

• 31 leading diabetes drugs including
o Lantus
o Januvia
o NovoLog
o Humalog
o Levemir

• Leading diabetes drug manufacturers including:
o Novo Nordisk
o Sanofi-Aventis
o Merck (MSD)
o Eli Lilly

• Strengths, weaknesses, opportunities and threats of the global diabetes drugs market. Discussions include
o The emergence of new drug classes and biosimilars
o The rising cost of drug production and risk of cardiovascular complications

Recent News

“Pharmaceutical Contract Manufacturing market set to grow to $138bn by 2024” says new Visiongain report

The technologies that will be in the greatest demand in this decade are those that provide flexibility and faster turnover times for pharma companies.

19 August 2019

Read

“Global Ophthalmic Drugs market set to grow to $32bn by 2024” says Visiongain report

Successful harnessing of the opportunities for growth in the ophthalmic pharmaceuticals market will depend upon the development of novel products with technologies that increase clinical effectiveness and development of products for previously-untreated ophthalmic conditions.

15 August 2019

Read

“Global Medical Device Contract Manufacturing market set to grow to $130bn by 2024” says new Visiongain report

The available reduced costs of outsourced manufacturing combined with access to the innovation power of CMOs are major drivers behind the decision to outsource manufacturing processes.

06 August 2019

Read

“3D Printing for Healthcare market is worth $872 million in 2019” says Visiongain report

The main appeal of 3D printed healthcare products to professionals is that each unit can be personalised to fit the recipient.

02 August 2019

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever